Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Tag Archives: Barack Obama
Obama Reveals Healthcare Reform Plan
Image via Wikipedia
The health reform proposal unveiled by the White House on Feb. 22, 2010 retains a number of provisions that directly affect drug coverage and industry revenues. The plan highlights that it will close the Medicare drug benefit “doughnut hole” by 2020 to make drugs more affordable to the elderly. Seniors will get some [...]
Posted in News, Regulatory | Also tagged generics, healthcare reform, Medicaid, Medicare, pay-for-delay | 3 Comments
Will Healthcare Reform Pay Off?
Written by Jordan Melnick
Members of Congress are in for a hard landing when they get back from recess in early September. After four weeks at home in their districts, the debate will heat up again as they resume the arduous process of crafting the biggest piece of President Obama’s domestic agenda. With the president demanding [...]
Posted in Regulatory | Also tagged Health, Health care, Insurance, Medicare, pharmaceutical industry, Pharmaceutical Research and Manufacturers of America, White House | Leave a comment
Tauzin to Boehner: Don’t “Bully†Me
Image via Wikipedia
PhRMA chief Billy Tauzin so far shows no sign of waving the white flag in response to an accusatory missive from House Minority Leader Rep. John Boehner bludgeoning his former Republican colleague for leading the drug industry’s support of President Obama’s healthcare reform effort. Pointedly CC’d to pharma CEOs – Tauzin’s employers—and simultaneously [...]
The UK NHS is Many Things. Evil isn’t One of Them.
Far be it from me to politicize this blog, but I have great trouble understanding how anyone can brand a system based on the principles of providing healthcare for all as ‘evil’.Â
The UK NHS has many flaws. It is over-stretched, weary, beleaguered, underfunded, occasionally incompetent, occasionally misguided, in parts outmoded, over-managed and often frustrating. But [...]
Posted in Global, Regulatory | Also tagged CEOs, health insurance, healthcare reform, socialized healthcare, UK National Health Service | 1 Comment

Elmendorf Refuses to Go Quietly Into the Night of HCR